Helping patients access the treatment they need is extremely important, especially when it can involve loss of vision caused by retinal disease.
For a newly diagnosed patient, finding out they have a retinal disease like Wet Age-related Macular Degeneration (Wet AMD), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR) can be overwhelming and intimidating. In addition to the fears and uncertainty of losing vision, patients are often faced with access issues to receive treatment. The EYLEA4U program can be an option to help provide assistance for patients prescribed EYLEA® (aflibercept) Injection.
EYLEA is a prescription medicine administered by injection into the eye. Patients should not use EYLEA if they have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept. Please see additional Important Safety Information below, including link to full Prescribing Information.
Regeneron is proud to offer the EYLEA4U program, a comprehensive patient support program for EYLEA. EYLEA is the only FDA-approved treatment in its class to provide the same treatment dose strength for Wet AMD, DME, DR and Macular Edema following Retinal Vein Occlusion.
The EYLEA healthcare provider website (https://www.hcp.eylea.us/eylea4u/reimbursement-support) includes a specific EYLEA4U Program page, featuring useful background on the EYLEA4U patient enrollment form and process, provider tools for physicians, an ICD-10 code finder for EYLEA, and other useful resources for providers to share with patients concerned about EYLEA access or interested in learning more about the EYLEA4U program.
Physicians also have access to links for useful patient resources, including brochures with disease information, eyecare tip sheets, and discussion guides for those newly diagnosed and nervous about navigating life with a retinal disease.
For eligible commercially insured patients who may need help with some of the copay costs of EYLEA, the EYLEA Copay Card Program may be available. Eligible patients may pay as little as $0 copay for each EYLEA treatment up to $15,000 in assistance per year toward product-specific copay, coinsurance, and insurance deductibles for EYLEA treatments.1
The EYLEA4U Patient Assistance Program may be able to provide EYLEA at no cost to eligible patients who are uninsured or lack coverage for EYLEA. Patients must meet all program eligibility criteria, including household income limits, to qualify.2
Patients who need help paying for their EYLEA out-of-pocket costs can apply for assistance through independent charitable foundations, however, Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided.
EYLEA4U also offers claims and appeal support, which may include reviewing the status of an EYLEA claim with a patient’s insurer or explaining an insurer’s appeal process.
Since 2011, EYLEA4U has conducted nearly 1.5 million benefits investigations on behalf of patients, providing over 4.4 million total support services to eligible patients. With EYLEA4U Connect, a streamline enrollment process available on the EYLEA4U Provider Portal or a third-party tablet,3 more than 40% of patients receiving electronic benefits verification within 60 seconds,4 the process gives physicians a new way to help them get connected with the support offered by EYLEA4U.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
CONTRAINDICATIONS
- EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
WARNINGS AND PRECAUTIONS
- Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
ADVERSE REACTIONS
- Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
- The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
- Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.
INDICATIONS
EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
Visit www.eylea4ueportal.com today to learn more about the support EYELA4U can offer patients prescribed EYLEA, or call 1-855-EYLEA4U (1-855-395-3248) and press Option 4. Hours: Mon-Fri 9 a.m. – 8 p.m. Eastern Time.
Please see accompanying full Prescribing Information.
1. Not an insurance or debit card program. This program is not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE, or similar federal or state programs. This program does not cover or provide support for supplies, procedures, or any physician-related service associated with EYLEA. General, non–product-specific copay, coinsurance, or insurance deductibles are not covered. This program is not valid where prohibited by law, taxed, or restricted. EYLEA4U reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional program conditions apply. See EYLEA.com.
2. Additional program terms and conditions apply.
3. Requires the use of a tablet provided by Regeneron’s third party technology source and a license paid for by the provider.
4. Within 60 seconds, EYLEA4U will provide either a full benefit verification or notification that manual processing is required. Of the patients who received a benefit verification through EYLEA4U as of January 2020, over 40% received a full benefit verification report within 60 seconds. Manual processing may take up to 48 hours.
6/2021 EYL.21.03.0121
